Advanced renal cell carcinoma management: the Latin American Cooperative Oncology Group (LACOG) and the Latin American Renal Cancer Group (LARCG) consensus update.
Andrey SoaresFernando Sabino Marques MonteiroKarine Martins da TrindadeAdriano Gonçalves E SilvaAna Paula Garcia CardosoAndré Deeke SasseAndré Poisl FayAndré Paternò Castello Dias CarneiroAntonio Machado Alencar JuniorAugusto César de Andrade MotaBruno SantucciDaniel M GirardiDaniel HerchenhornDaniel Vilarim AraújoDenis Leonardo Fontes JardimDiogo Assed BastosDiogo Rodrigues RosaFabio A SchutzFábio Roberto KaterFelipe da Silva MarinhoFernando Cotait MalufFernando Nunes Galvão de OliveiraFernando V de PaduaIgor Alexandre Protzner MorbeckJose Augusto Rinck JúniorLeonardo Atem G A CostaManuel Caitano Dias Ferreira MaiaManuela ZereuMarcelo Roberto Pereira FreitasMariane Sousa Fontes DiasMilena Shizue TarikiPamela MunizPatrícia Medeiros Milhomem BeatoPaulo Sérgio Moraes LagesPedro Isaacsson VelhoRicardo Saraiva de CarvalhoRodrigo Coutinho MarianoSandro Roberto De Araujo CavalleroThiago Martins OliveiraVinicius Carrera SouzaOren SmaletzStenio de Cassio ZequiPublished in: Journal of cancer research and clinical oncology (2024)
Immunotherapy and targeted therapy are the standards of care for advanced disease. The utilization and sequencing of these therapeutic agents hinge upon individual risk scores and responses to previous treatments. This consensus reflects a commitment to informed decision-making, drawn from professional expertise and evidence in the medical literature.